Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
|
| gptkbp:activities |
inhibits fungal cell membrane synthesis
broad-spectrum antifungal |
| gptkbp:approves |
gptkb:1990
gptkb:FDA |
| gptkbp:brand |
Diflucan
|
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
concurrent use with certain medications
hypersensitivity to fluconazole |
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:dosage_form |
oral tablet
oral suspension IV solution |
| gptkbp:duration |
depends on infection type
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fluconazole
|
| gptkbp:indication |
systemic fungal infections
esophageal candidiasis cryptococcal meningitis fungal infections in HIV/ AIDS patients oropharyngeal candidiasis vaginal candidiasis |
| gptkbp:ingredients |
C13 H12 F2 N6 O3
|
| gptkbp:interacts_with |
gptkb:phenytoin
gptkb:rifampin gptkb:warfarin |
| gptkbp:is_atype_of |
J02 A C01
|
| gptkbp:is_available_on |
gptkb:tablet
suspension injection |
| gptkbp:is_used_for |
treating fungal infections
treating candidiasis preventing fungal infections in immunocompromised patients |
| gptkbp:lifespan |
30 hours
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:metabolism |
liver
|
| gptkbp:name |
essential medicines
|
| gptkbp:research_areas |
pharmacokinetics
drug interactions clinical efficacy antifungal resistance |
| gptkbp:side_effect |
dizziness
headache nausea abdominal pain liver toxicity QT prolongation |
| gptkbp:type_of |
86386-73-4
|